These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1826243)

  • 1. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy.
    Paterson KR; Wilson M; Kesson CM; Buchan M; Roberts M; Reith SB; Davidson E
    Diabet Med; 1991 Jan; 8(1):40-3. PubMed ID: 1826243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
    Holman RR; Steemson J; Turner RC
    Diabet Med; 1987; 4(5):457-62. PubMed ID: 2959438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas.
    Wolffenbuttel BH; Weber RF; Weeks L; van Koetsveld PM; Verschoor L
    Diabetes Res; 1990 Feb; 13(2):79-84. PubMed ID: 2091874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
    Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE
    Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.
    Davidson MB; Raskin P; Tanenberg RJ; Vlajnic A; Hollander P
    Endocr Pract; 2011; 17(3):395-403. PubMed ID: 21324825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
    Holman RR; Steemson J; Turner RC
    Diabetes Res; 1991 Dec; 18(4):149-53. PubMed ID: 1842749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
    Diabetes; 1985 Aug; 34(8):793-8. PubMed ID: 2862087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin therapy in type II diabetes.
    Holman RR; Turner RC
    Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S179-84. PubMed ID: 8529512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus.
    Kawamori R; Iwamoto Y; Kadowaki T; Iwasaki M; Kim SW; Woo JT; Baik SH; Yoon KH
    Diabetes Obes Metab; 2009 Sep; 11(9):900-9. PubMed ID: 19614946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in morning hyperglycaemia with basal human ultratard and prandial human actrapid insulin--a comparison of multiple injection regimens.
    Davies RR; McEwen J; Moreland TA; Durnin C; Newton RW
    Diabet Med; 1988 Oct; 5(7):671-5. PubMed ID: 2975553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L; Merilainen M; Karwe V; Raskin P;
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.